CA2934828A1 - Prostate cancer gene profiles and methods of using the same - Google Patents

Prostate cancer gene profiles and methods of using the same Download PDF

Info

Publication number
CA2934828A1
CA2934828A1 CA2934828A CA2934828A CA2934828A1 CA 2934828 A1 CA2934828 A1 CA 2934828A1 CA 2934828 A CA2934828 A CA 2934828A CA 2934828 A CA2934828 A CA 2934828A CA 2934828 A1 CA2934828 A1 CA 2934828A1
Authority
CA
Canada
Prior art keywords
genes
patient
prostate cancer
expression
probes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2934828A
Other languages
English (en)
French (fr)
Inventor
Shiv K. Srivastava
Albert Dobi
Gyorgy Petrovics
Thomas Werner
Martin Seifert
Matthias Scherf
Original Assignee
GENOMATIX
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENOMATIX, Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical GENOMATIX
Publication of CA2934828A1 publication Critical patent/CA2934828A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
CA2934828A 2013-12-30 2014-12-29 Prostate cancer gene profiles and methods of using the same Abandoned CA2934828A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361921739P 2013-12-30 2013-12-30
US61/921,739 2013-12-30
PCT/US2014/072610 WO2015103166A1 (en) 2013-12-30 2014-12-29 Prostate cancer gene profiles and methods of using the same

Publications (1)

Publication Number Publication Date
CA2934828A1 true CA2934828A1 (en) 2015-07-09

Family

ID=53493959

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2934828A Abandoned CA2934828A1 (en) 2013-12-30 2014-12-29 Prostate cancer gene profiles and methods of using the same

Country Status (8)

Country Link
US (1) US20160326594A1 (https=)
EP (1) EP3090265B1 (https=)
JP (1) JP2017509351A (https=)
CN (1) CN106796236A (https=)
AU (1) AU2014373927B2 (https=)
CA (1) CA2934828A1 (https=)
WO (1) WO2015103166A1 (https=)
ZA (1) ZA201604370B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2017127550A1 (en) * 2016-01-19 2017-07-27 Wayne State University Prostate cancer aggressiveness gene signatures for subjects of african or european descent
US11913076B2 (en) * 2017-05-12 2024-02-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
WO2019169336A1 (en) * 2018-03-02 2019-09-06 The Johns Hopkins University Methods for prostate cancer detection
CN110054674B (zh) * 2019-03-07 2022-08-05 深圳市龙华区人民医院 免疫原性多肽以及抗ttc36抗体ap2-19及应用
CN110628908B (zh) * 2019-09-19 2022-05-10 北京恩泽康泰生物科技有限公司 用于前列腺癌诊断分级和良恶性预测的生物标志物及检测试剂盒
AU2021291728A1 (en) * 2020-06-18 2022-02-24 Ontario Institute For Cancer Research (Oicr) Molecular classifiers for prostate cancer
CN111893177B (zh) * 2020-08-19 2022-10-04 南通大学 遗传性耳聋诱导基因的突变筛选方法及突变检测试剂盒
CN113284559B (zh) * 2021-07-21 2021-10-15 暨南大学 一种物种基因组的启动子查询方法、系统及设备
CN120118995A (zh) * 2024-09-25 2025-06-10 深圳汇芯生物医疗科技有限公司 用于检测前列腺癌生物标志物的引物组、探针组、试剂盒及方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US20050032065A1 (en) * 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
EP2383350B1 (en) * 2004-05-07 2018-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
WO2006056766A2 (en) * 2004-11-24 2006-06-01 St George's Enterprises Limited Diagnosis of prostate cancer
CN101310185A (zh) * 2005-09-19 2008-11-19 约翰·霍普金斯大学 前列腺癌的生物标记
US8338109B2 (en) * 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2074422A4 (en) * 2006-11-13 2010-02-17 Life Technologies Corp METHOD AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS
JP5781922B2 (ja) * 2008-04-10 2015-09-24 ザ ヘンリー エム.ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン,インコーポレーテッド Erg遺伝子発現における前立腺癌特異的変化ならびにそれらの変化に基づく検出および治療方法
CA2745961A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
FR2945820A1 (fr) * 2009-05-25 2010-11-26 Univ Clermont Auvergne Panel de genes pour le pronostic du cancer de la prostate
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
MX338883B (es) * 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
JP2013540995A (ja) * 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. 疾患に対する循環バイオマーカー
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
ES2593959T3 (es) * 2011-04-19 2016-12-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Marcadores del cáncer de próstata
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
CN103874770A (zh) * 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
JP2014525584A (ja) * 2011-08-31 2014-09-29 オンコサイト コーポレーション 癌の治療および診断のための方法および組成物
SE536352C2 (sv) * 2011-10-24 2013-09-03 Chundsell Medicals Ab Markörgener för klassificiering av prostatacancer
ES2616129T3 (es) * 2011-11-04 2017-06-09 Mdxhealth Research B.V. Combinaciones de marcadores moleculares en cáncer de próstata que proporcionan una herramienta para diagnóstico con mejor sensibilidad/especificidad
US9863002B2 (en) * 2012-06-04 2018-01-09 North Carolina Central University Genetic determinants of prostate cancer risk

Also Published As

Publication number Publication date
EP3090265B1 (en) 2020-04-08
WO2015103166A1 (en) 2015-07-09
AU2014373927A1 (en) 2016-07-07
JP2017509351A (ja) 2017-04-06
ZA201604370B (en) 2020-12-23
EP3090265A4 (en) 2018-03-21
EP3090265A1 (en) 2016-11-09
CN106796236A (zh) 2017-05-31
AU2014373927B2 (en) 2018-03-22
US20160326594A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
EP3090265B1 (en) Prostate cancer gene profiles and methods of using the same
JP6285009B2 (ja) 前立腺ガンの予後の検知及び判定のための組成物及び該検知及び判定方法
US10711311B2 (en) Genomic rearrangements associated with prostate cancer and methods of using the same
US20250369053A1 (en) Recurrence gene signature across multiple cancer types
US20240218451A1 (en) Prostate cancer gene profiles and methods of using the same
US20150344962A1 (en) Methods for evaluating breast cancer prognosis
WO2010108638A9 (en) Tumour gene profile
US10081842B2 (en) Prostate cancer gene expression profiles
US20220033913A1 (en) Genomic rearrangements associated with prostate cancer and methods of using the same
WO2021178832A2 (en) Dna damage repair genes in cancer
AU2024226127A1 (en) Methods for diagnosing and treating ovarian cancer
HK1238718A1 (en) Prostate cancer gene profiles and methods of using the same
CA2934878C (en) Genomic rearrangements associated with prostate cancer and methods of using the same
EP2607494A1 (en) Biomarkers for lung cancer risk assessment
HK1238683A1 (en) Genomic rearrangements associated with prostate cancer and methods of using the same
EP2814982A1 (en) New method for prognosing the survival of patients suffering from chronic myelomonocytic leukaemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191029

FZDE Discontinued

Effective date: 20240206